

Jean-Luc Raoul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/624961/publications.pdf>

Version: 2024-02-01

40
papers

23,704
citations

430874
18
h-index

276875
41
g-index

44
all docs

44
docs citations

44
times ranked

24260
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 378-390. | 27.0 | 12,004 |
| 2 | FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 2011, 364, 1817-1825. | 27.0 | 6,140 |
| 3 | Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 501-513. | 27.0 | 2,216 |
| 4 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology, 2012, 57, 821-829. | 3.7 | 736 |
| 5 | Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. Journal of Clinical Oncology, 2013, 31, 3517-3524. | 1.6 | 675 |
| 6 | Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. Journal of Clinical Oncology, 2013, 31, 3509-3516. | 1.6 | 544 |
| 7 | Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer, 2012, 118, 147-156. | 4.1 | 250 |
| 8 | Predictive Value of ¹⁸ F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors. Journal of Nuclear Medicine, 2009, 50, 858-864. | 5.0 | 224 |
| 9 | Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology, 2017, 66, 1166-1172. | 3.7 | 178 |
| 10 | High Prognostic Value of ¹⁸ F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation. Journal of Nuclear Medicine, 2014, 55, 1786-1790. | 5.0 | 153 |
| 11 | Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2011, 17, 1973-1983. | 7.0 | 142 |
| 12 | Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of Hepatology, 2012, 56, 1080-1088. | 3.7 | 109 |
| 13 | Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut, 2010, 59, 1527-1534. | 12.1 | 70 |
| 14 | Sorafenib: Experience and Better Management of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer, 2019, 8, 457-467. | 7.7 | 42 |
| 15 | A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract cancers. European Journal of Cancer, 2020, 140, 37-44. | 2.8 | 37 |
| 16 | Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepatic Oncology, 2019, 6, HEP11. | 4.2 | 24 |
| 17 | An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2017, 18, 1467-1476. | 1.8 | 23 |
| 18 | Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer, 2014, 3, 439-450. | 7.7 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. JAMA Network Open, 2021, 4, e2113739. | 5.9 | 19 |
| 20 | Hepatocellular Carcinoma in a Noncirrhotic Liver after Long-Term Use of Danazol for Hereditary Angioedema. Case Reports in Oncology, 2014, 7, 825-827. | 0.7 | 11 |
| 21 | Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. Journal of Gastrointestinal Cancer, 2016, 47, 15-19. | 1.3 | 10 |
| 22 | Acrokeratosis Paraneoplastica (Bazex Syndrome) Associated With Metastatic Squamous Cell Esophageal Carcinoma. Journal of Clinical Oncology, 2008, 26, 5128-5129. | 1.6 | 9 |
| 23 | Bazex Syndrome Revealing a Gastric Cancer. Case Reports in Oncology, 2014, 7, 285-287. | 0.7 | 7 |
| 24 | An elevated serum alkaline phosphatase level in hepatic metastases of grade 1 and 2 gastrointestinal neuroendocrine tumors is unusual and of prognostic value. PLoS ONE, 2017, 12, e0177971. | 2.5 | 7 |
| 25 | Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Cancers, 2022, 14, 1156. | 3.7 | 6 |
| 26 | Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study. Cancers, 2021, 13, 3389. | 3.7 | 5 |
| 27 | A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study. Supportive Care in Cancer, 2017, 25, 2715-2722. | 2.2 | 4 |
| 28 | Significance of lymph node involvement in local recurrence of colorectal cancer. Journal of Surgical Oncology, 2019, 120, 722-728. | 1.7 | 4 |
| 29 | Radiosensitizing Chemotherapy (Irinotecan) with Stereotactic Body Radiation Therapy for the Treatment of Inoperable Liver and/or Lung Metastases of Colorectal Cancer. Cancers, 2021, 13, 248. | 3.7 | 4 |
| 30 | Retrorectal Mucinous Adenocarcinoma Arising from a Tailgut Cyst: A Case Report. Case Reports in Oncology, 2021, 14, 147-151. | 0.7 | 4 |
| 31 | Solid Pseudopapillary Tumor of the Pancreas: One Case with a Metastatic Evolution in a Caucasian Woman. Case Reports in Oncology, 2015, 8, 405-408. | 0.7 | 3 |
| 32 | COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19). Clinical Medicine Insights: Oncology, 2022, 16, 117955492210901. | 1.3 | 3 |
| 33 | Why is pancreatic cancer difficult to treat in the elderly?. Aging Health, 2012, 8, 301-307. | 0.3 | 2 |
| 34 | To TACE or not to TACE? Lessons from a negative trial. The Lancet Gastroenterology and Hepatology, 2017, 2, 541-543. | 8.1 | 2 |
| 35 | Intra-abdominal recurrence from colorectal carcinoma: Differences and similarities between local and peritoneal recurrence. Surgical Oncology, 2020, 32, 23-29. | 1.6 | 2 |
| 36 | Transient Vision Loss – A Rare Oxaliplatin-Induced Ophthalmologic Side Effect: A Report of Two Cases. Case Reports in Oncology, 2021, 14, 483-486. | 0.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Isolated Splenic Metastases of Her2+++ Gastroesophageal Junction Adenocarcinoma. Case Reports in Oncology, 2016, 9, 154-157. | 0.7 | 1 |
| 38 | Prognostication of HCC under sorafenib: Is it always possible?. Liver International, 2020, 40, 1241-1243. | 3.9 | 1 |
| 39 | BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report. Case Reports in Oncology, 2019, 12, 426-429. | 0.7 | 0 |
| 40 | Survival after cytoreductive surgery for peritoneal metastases in colorectal cancer patients: Does a history of resected liver metastases worsen the prognosis?. European Journal of Surgical Oncology, 2022, 48, 803-809. | 1.0 | 0 |